% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Perna:285362,
      author       = {L. Perna and H. Stocker$^*$ and L. Burow and L. Beyer and
                      K. Trares$^*$ and C. Kurz and S. Gürsel and B.
                      Holleczek$^*$ and M. Tatò and K. Beyreuther and U. Mons and
                      K. Gerwert and R. Perneczky and B. Schöttker$^*$ and H.
                      Brenner$^*$},
      title        = {{S}ubjective cognitive complaints and blood biomarkers of
                      neurodegenerative diseases: a longitudinal cohort study.},
      journal      = {Alzheimer's research $\&$ therapy},
      volume       = {15},
      number       = {1},
      issn         = {1758-9193},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2023-02331},
      pages        = {198},
      year         = {2023},
      note         = {#LA:C070#},
      abstract     = {Subjective cognitive complaints (SCC) have been mostly
                      studied in the context of Alzheimer's disease in memory
                      clinic settings. The potential of combining SCC with genetic
                      information and blood biomarkers of neurodegenerative
                      diseases for risk assessment of dementia and depression in
                      the absence of dementia among community-dwelling older
                      adults has so far not been explored.Data were based on a
                      population-based cohort of 6357 participants with a 17-year
                      follow-up (ESTHER study) and a clinic-based cohort of 422
                      patients. Participants of both cohorts were grouped
                      according to the diagnosis of dementia (yes/no) and the
                      diagnosis of depression in the absence of dementia (yes/no).
                      Participants without dementia included both cognitively
                      unimpaired participants and cognitively impaired
                      participants. Genetic information (APOE ε4 genotype) and
                      blood-based biomarkers of neurodegenerative diseases (glial
                      fibrillary acidic protein; GFAP, neurofilament light chain;
                      NfL, phosphorylated tau181; p-tau181) were available in the
                      ESTHER study and were determined with Simoa Technology in a
                      nested case-control design. Logistic regression models
                      adjusted for relevant confounders were run for the outcomes
                      of all-cause dementia and depression in the absence of
                      dementia.The results showed that persistent SCC were
                      associated both with increased risk of all-cause dementia
                      and of depression without dementia, independently of the
                      diagnostic setting. However, the results for the ESTHER
                      study also showed that the combination of subjective
                      complaints with APOE ε4 and with increased GFAP
                      concentrations in the blood yielded a substantially
                      increased risk of all-cause dementia (OR 5.35; $95\%CI$
                      3.25-8.81, p-value < 0.0001 and OR 7.52; $95\%CI$
                      2.79-20.29, p-value < 0.0001, respectively) but not of
                      depression. Associations of NfL and p-tau181 with risk of
                      all-cause dementia and depression were not statistically
                      significant, either alone or in combination with SCC, but
                      increased concentrations of p-tau181 seemed to be associated
                      with an increased risk for depression.In community and
                      clinical settings, SCC predict both dementia and depression
                      in the absence of dementia. The addition of GFAP could
                      differentiate between the risk of all-cause dementia and the
                      risk of depression among individuals without dementia.},
      keywords     = {Humans / Aged / Longitudinal Studies / Neurodegenerative
                      Diseases: diagnosis / Apolipoprotein E4: genetics /
                      Alzheimer Disease: diagnosis / Alzheimer Disease: genetics /
                      Cohort Studies / Cognition / Biomarkers / tau Proteins:
                      metabolism / Amyloid beta-Peptides: metabolism / APOE ε4
                      (Other) / Dementia (Other) / Depression (Other) / Glial
                      fibrillary acidic protein (Other) / Older people (Other) /
                      Subjective cognitive decline (Other) / Apolipoprotein E4
                      (NLM Chemicals) / Biomarkers (NLM Chemicals) / tau Proteins
                      (NLM Chemicals) / Amyloid beta-Peptides (NLM Chemicals)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37951931},
      pmc          = {pmc:PMC10638700},
      doi          = {10.1186/s13195-023-01341-3},
      url          = {https://inrepo02.dkfz.de/record/285362},
}